Early cerebrospinal fluid elevations of pTau-217 in severe traumatic brain injury subjects.

ABSTRACT:

Introduction

Tauopathies, including Alzheimer's disease (AD), feature abnormal accumulations of hyperphosphorylated Tau protein; however, their biomarker potential in traumatic brain injury (TBI) is not well-defined. This study investigated whether cerebrospinal fluid (CSF) phosphorylated Tau at threonine-217 (pTau-217) could serve as an early biomarker for severe TBI (sTBI).

Methods

CSF samples from 26 sTBI patients, collected between 6 and 240 h post-injury, and 19 healthy controls were analyzed using an optimized direct enzyme-linked immunosorbent assay (ELISA; sensitivity <4.7 pg/mL) for pTau-217 detection, complemented by Western blot validation. Temporal analysis, ROC curves, and trajectory clustering were used for interpretation.

Results

CSF pTau-217 levels wer

SUBMITTER: Yadikar H 

PROVIDER: S-EPMC12344560 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature